Efficacy of Acupuncture and Moxibustion Treatment in Patients With Quiescent Crohn's Disease:Evaluation With fMRI

Efficacy of Acupuncture and Moxibustion Treatment in Patients With Quiescent Crohn's Disease:Evaluation With Functional Magnetic Resonance Imaging(fMRI)

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01696838

Enrollment

Registered

2012-10-01

Start date

2012-09-30

Completion date

2014-11-30

Last updated

2016-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CAM, Crohn's Disease

Keywords

Crohn's disease, acupuncture, moxibustion, fMRI, Gut

Brief summary

The purpose of this study is to determine whether acupuncture or moxibustion therapies are effective in the treatment of Crohn's disease. Meanwhile, the investigators aim to evaluate the efficacy by functional magnetic resonance imaging.

Detailed description

The purpose of this study is to determine whether acupuncture or moxibustion therapies are effective in the treatment of Crohn's disease. meanwhile, the investigators aim to evaluate the efficacy by functional magnetic resonance imaging. Through treating quiescent Crohn's disease by electroacupuncture or moxibustion therapies for 12 weeks, Compare the different brain activation by the different therapies and observe the correlation between brain activation and efficacy.

Interventions

OTHERelectroacupuncture

Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.

OTHERmoxibustion

patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* age 18-50 years; * right-handed; * clinical remission (Crohn's Disease Activity Index \[CDAI\]≤150) for at least 6 months prior to the study; * C-reactive protein(CRP)\<10 mg/l; * erythrocyte sedimentation rate (ESR) \<20 mm/h * signing awritten informed consent form.

Exclusion criteria

* use of corticosteroids and psychotropic medications in the previous 30 days; * current or prior history of neurological or psychiatric disease based * on physicians' examination and questionnaires; * current or prior history of neurosurgery, head injury, cerebrovascular * insult, or brain trauma involving loss of consciousness; * learning disability; * claustrophobia; * presence of metallic implants in the body; * being pregnant or during lactation.

Design outcomes

Primary

Measure	Time frame	Description
CDAI	1 year	Crohn's Disease Activity Index

Secondary

Measure	Time frame	Description
fMRI	1 year	Brain activiation tested by BOLD fMRI
IBDQ	1 year	Inflammatory Bowel Disease Questionnaire
Inflammatory factors	1 and a half years	Intestinal mucosa of IL-6,IL-17,IL-23,etc
Neurotransmitter	1 and a half years	5-HT,DA,etc

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026